

Case report

Effective treatment of eosinophilic granuloma in a cat using tacrolimus with prednisolone

Min-young Moon, Guk-Hyun Suh, Yong-Jin Kwon, Ha-Jung Kim*

Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Korea

A 2-year-old, spayed male Bengal cat was referred to our clinic due to a mass lesion on the upper lip, as well as lower lip swelling and redness. Furthermore, well-circumscribed, raised, pink lesions were found in the oral cavity. Complete blood counts (CBC) and serum biochemistry profiles revealed no remarkable findings. Bacterial and fungal cultures of the lesion in the oral cavity were negative. Fine needle aspiration of the lesions revealed numerous eosinophils. Based on both clinical examination and cytological evaluation, the cat was diagnosed with feline eosinophilic granuloma. As an initial treatment, oral prednisolone (PDS) with cyclosporine was administered. However, the cyclosporine caused the cat to vomit. The lesion was markedly improved after 2 weeks of PDS-only therapy; this was subsequently tapered for 2 months and discontinued. However, one month later, the lesion had relapsed. The cat was then treated for one month using tacrolimus with PDS, and the clinical signs of eosinophilic granuloma gradually improved. The tacrolimus was gradually tapered for 1 month, and the PDS was gradually tapered for 4 months. There is no standard protocol for the investigation and treatment of feline eosinophilic granuloma. The cat in this report was administered immunosuppressive therapies to treat eosinophilic granuloma. This case report provides evidence the combination of PDS and tacrolimus is effective for reducing relapse in feline eosinophilic granuloma.

Key words: cat, feline, eosinophilic granuloma, PDS, tacrolimus

Introduction

Feline eosinophilic granuloma complex, which is characterized by a group of lesions affecting the skin, mucocutaneous junctions, and oral cavity, is a common in-

flammatory skin disease in cats. Although the etiology of this condition is unknown, the histological appearance of lesions suggests an immune-mediated mechanism, possibly a hypersensitivity reaction to an unknown antigen [1,2,3,12,15,16,17,18,19]. Classically, three types of lesion have been characterized in feline eosinophilic granuloma complex: (1) the indolent ulcer, (2) the eosinophilic plaque, and (3) the eosinophilic granuloma [3,4,5]. In particular, eosinophilic granulomas occur on the caudal thighs, cheek, and oral cavity. The oral lesions can occur anywhere in the mouth, including the gingiva, hard and soft palates, oral and nasal pharynx, and tongue; occasionally, lesions even manifest in the draining lymphoid tissues [2,3,6]. Lesions in the oral cavity and on the face have a papular to nodular configuration [3], and cats with oral lesions may be dysphagic [1,2,6]. In addition, eosinophilia may occur in the blood, especially when oral lesions are present [2,3].

Tacrolimus is an immunosuppressive antibiotic of the macrolide family; it is 10- to 100-fold more potent than cyclosporine in the inhibition of T-cell activation [7,8,20]. The agent works by inhibiting calcineurin, a calcium-activated protein phosphatase, that is necessary for appropriate immune modulation [9]. A topical formulation of tacrolimus has been reported to be efficacious in the treatment of canine atopic dermatitis [10], but few efficacy and safety reports exist in the veterinary literature.

Case report

A spayed male Bengal cat showing swelling and redness in the lips and gingiva was referred to the department of veterinary internal medicine, Chonnam National University. Upon physical examination, swelling and redness on the upper and lower lips were found (Fig. 1). Furthermore, well-circumscribed, raised, and pink lesions were found

*Corresponding author: Ha-Jung Kim

College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Korea

Tel: +82-62-530-2886, E-mail: kimhj614@jnu.ac.kr

in the oral cavity. In general, the lesions on the lips and gingiva were well-circumscribed and not ulcerative.

There is no remarkable findings on Complete blood counts (CBC) and serum biochemistry profiles. Direct microscopy of cutaneous lesions was performed, using impression smear technique. Cytological examination of the lesions showed numerous eosinophils (Fig. 2). Bacterial and fungal cultures of the lesion in the oral cavity were negative.

Based on the clinical appearance and cytology, eosinophilic granuloma was diagnosed, and the lesions were initially treated using prednisolone (PDS; Solondo[®]; 1 mg/kg, p.o, bid; Yuhanyanghaeng, Seoul, South Korea) with cyclosporine (Cipol-N[®]; 5 mg/kg, p.o, sid; Jonggeundang, Seoul, South Korea) because the patient's history showed that a similar lesion had relapsed when treated using PDS-only therapy. At the next visit, the cyclosporine was withdrawn due to severe vomiting. PDS-only sole therapy was maintained for 2 month, with gradual tapering, before being discontinued. One month later, however, the lesion had relapsed. Because



Fig. 1. Feline eosinophilic granuloma. Note the swollen, erythematous lips and gingival lesions.




Fig. 2. Cytological feature of the upper lip lesion. Three eosinophils in the center can be seen on the impression film (Diff-Quick staining, $\times 1,000$).

of the recurrent relapse of the lesion, a new combination therapy was initiated; oral tacrolimus (Advagraf[®]; 0.3 mg/kg, p.o, bid; Astellas Pharm. Co., Netherlands) with PDS (Solondo[®]) was administered. The clinical signs improved gradually over the course of 1 week (Fig. 3). The tacrolimus was gradually tapered for 1 month, and the PDS was gradually tapered for 4 months. The oral lesion had not relapsed after 3 months of follow-up.

Discussion

The cat in this report was administered immunosuppressive therapies to treat eosinophilic granuloma. As an initial treatment, oral PDS with cyclosporine was administered. Several mild adverse events have been related to cyclosporine use in cats (salivation, vomiting, headshaking, intermittent soft feces, and gingival hyperplasia) [11]. In the present case, the cyclosporine was stopped due to vomiting.

Subsequently, PDS was combined with a new, trial formula of tacrolimus for 1 month, and the treatment showed efficacy in this case. The erythema and swelling of the lips and gingiva improved rapidly. Tacrolimus belongs to an important class of immunomodulators known as calcineurin inhibitors, which also include cyclosporine [13]. Calcineurin inhibitors also inhibit the activation of mast cells, basophils, eosinophils, keratinocytes, and Langerhans cells [13]. Both cyclosporine and tacrolimus decrease the number and activity of epidermal dendritic cells and down-regulate the expression of the high-affinity immunoglobulin E receptor on Langerhans cells [13]. Although similar to cyclosporine in its mechanism of activity, tacrolimus is structurally different [13]. Moreover, the potency of tacrolimus has been estimated at 10 to 100 times greater than that of cyclosporine [13]. More recently, additional applications have been reported, including



Fig. 3. Photograph of the skin lesions 4 weeks after prescription of tacrolimus. Note that the swelling and erythematous lesions of the lips and gingiva have improved.

treatment of actinic dermatosis, psoriasis, and the early stages of cutaneous T cell lymphoma [13].

There is no standard protocol for the investigation and treatment of feline eosinophilic granuloma. Systemic treatment using other immunosuppressants that act on T cells (e.g. cyclosporine or glucocorticoids) is the only reported recommendation. Although PDS is fast and effective in the treatment of eosinophilic granuloma in cats, long-term systemic glucocorticoid treatment can lead to adverse glucocorticoid-induced effects. Furthermore, in the present case, severe eosinophilic granuloma relapsed after PDS tapering. Therefore, the combination of PDS and tacrolimus was a good choice in the present case, because the recurrent relapses stopped.

In contrast, in human patients undergoing solid organ transplant, tacrolimus induces thrombocytopenia [14]. Therefore, the use of tacrolimus in feline eosinophilic granuloma should be investigated in more cases.

In conclusion, the present case indicated that the combination of PDS and tacrolimus is effective for reducing relapse in feline eosinophilic granuloma. To our knowledge, this is the first report to successfully combine tacrolimus with PDS in the long-term treatment of feline eosinophilic granuloma.

Acknowledgements

This work was supported by Chonnam National University (Grant number: 2016-2871). In addition, this work was also supported by the Ministry of Agriculture, Food and Rural Affairs, Republic of Korea (Grant No. 315016-3-C00).

ORCID

Ha-Jung Kim, <http://orcid.org/0000-0002-7202-8155>

References

- Merchant, S. R. Diagnosis of feline skin disease based on cutaneous reaction patterns. *Compend Contin Educ Pract Vet* 1994;16:163–166.
- Song MD. Diagnosing and treating feline eosinophilic granuloma complex. *Vet Med* 1994;89:1141–1145.
- Scott DW, Miller WH, Griffin CE. Muller and Kirk's *Small Animal Dermatology*. 6th ed. Philadelphia: W. B. Saunders; 2001. p. 1148–1153.
- MacEwen EG, Hess PW. Evaluation of effect of immunomodulation on the feline eosinophilic granuloma complex. *J Am Anim Hosp Assoc* 1987;23:519–525.
- Fondati A, Fondevila D, Ferrer L. Histopathological study of feline eosinophilic dermatoses. *Vet Dermatol* 2001;6:333–338.
- Medleau L, Hnilica K. *Small Animal Dermatology, A Color Atlas and Therapeutic Guide*. Philadelphia: W. B. Saunders; 2001. p. 254–258.
- Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a *Streptomyces*. I. Fermentation, isolation, and physico-chemical and biological characteristics. *J Antibiotics* 1987;40:1249.
- Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a *Streptomyces*. II: Immunosuppressive effect of FK-506 in vitro. *J Antibiotics* 1987;40:1256–1265.
- Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. *Immunol Today* 1992;13:136–142.
- Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic®) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. *Vet Dermatol* 2004;15:294–303.
- Latimer KS, Rakich PM, Purswell BJ, Kircher IM. Effects of cyclosporin A administration in cats. *Article Veterinary Immunology and Immunopathology* 1986;11:161-173.
- Pressanti C, Cadiergues MC. Feline familial pedal eosinophilic dermatosis in two littermates. *JFMS open reports* 2015;1(1):2055116915579683.
- John D. Bonagura, David C. Twedt. *Kirk's Current Veterinary Therapy XIV*: Elsevier Health Sciences; 2008.
- Hassan A, Naveen M, Rakesh PM. Tacrolimus Induced Refractory Immune Thrombocytopenia. *Blood* 2010;116:1426.
- Buckley L, Nuttall T. Feline eosinophilic granuloma complexities: some clinical clarification. *J Feline Med Surg* 2012;14:471–481.
- Leistra WH, van Oost BA, Willemse T. Non-pruritic granuloma in Norwegian forest cats. *Vet Rec* 2005;156:575–577.
- Power HT. Eosinophilic granuloma in a family of specific pathogen-free cats. *Proceedings of the American Academy of Veterinary Dermatology/American College of Veterinary Dermatology*. San Francisco: 1990. p. 45.
- Fondati A, Fondevila D, Ferrer L. Histopathological study of feline eosinophilic dermatoses. *Vet Dermatol* 2001;12:333–338.
- Bloom PB. Canine and feline eosinophilic skin diseases. *Vet Clin North Am Small Anim Pract* 2006;36:141–160.
- Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee W, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. *Clin Pharmacol Ther* 1997;62:41–49.